Ramipril Recall Issued for Blood Pressure Capsules Due to Packaging Error

Ramipril recall: Crescent Pharma Limited is initiating a precautionary recall of one batch of Ramipril 2.5mg capsules due to a packaging error. There is a possibility that some cartons may contain blister strips of a higher dosage, specifically Ramipril 10mg. This recall comes after a healthcare professional discovered two blister strips of Ramipril 10mg capsules inside a sealed carton of Crescent Pharma Limited Ramipril 2.5mg capsules. The affected batches were produced at the same facility, and the mishap occurred during the packaging phase. Ramipril is commonly prescribed for managing hypertension (high blood pressure), kidney disorders, and heart failure. Dr. Alison Cave, Chief Safety Officer at MHRA, has stated, "If you are using Crescent Pharma Limited Ramipril 2.5mg capsules, please check the packaging for the batch number GR155023. This information, along with the expiry date, is located on the outer carton. If you possess this batch, ensure the strength indicated on the carton matches the blister strips inside." Dr. Cave continued, "If the carton of Crescent Pharma Limited Ramipril 2.5mg contains blister strips labeled as Ramipril 10mg capsules, refrain from taking the medication. Instead, please reach out to your dispensing pharmacy. Conversely, if the carton contains the correctly labeled Ramipril 2.5mg capsules, no further action is needed, and you may continue your treatment as usual." "If you possess an affected pack or have received this batch earlier and believe you've consumed any Ramipril 10mg capsules in error, and are now experiencing side effects, seek medical advice promptly. Potential symptoms include dizziness, fainting, fatigue, or altered kidney function—these may pose greater risks for vulnerable patients. The impact of taking a higher dose of Ramipril should be evaluated by a healthcare professional to determine if any examinations or tests are necessary." "Should you have this batch of medication, bring along the leaflet that accompanied your medicine, as well as any remaining tablets, to your pharmacy or GP practice. Additionally, any suspected side effects should be reported through the MHRA Yellow Card scheme." The MHRA has recommended that pharmacies and healthcare providers cease distribution of the affected batch and return all remaining stock to their suppliers. For more information on medication recalls, visit the [FDA](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts) or the [MHRA](https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency). For those who want to learn more about health risks associated with medication dosage errors, visit [www.globemigrant.com/resource](http://www.globemigrant.com/resource) and [www.globemigrant.com/health](http://www.globemigrant.com/health). Source: https://www.gov.uk/government/news/precautionary-recall-of-blood-pressure-medication-crescent-pharma-limited-ramipril-25mg-capsules

No Result